
Hironaga Satake

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1259045/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Phase II study of S-1 and oxaliplatin as neoadjuvant chemotherapy for locally advanced adenocarcinoma of the gastric or esophagogastric junction: KSCC1601. Gastric Cancer, 2022, 25, 180-187.	2.7	10
2	Pathological Complete Response of Clinical T4b Ascending Colon Cancer after Preoperative Chemotherapy Using Pembrolizumab. Case Reports in Oncology, 2022, 14, 1497-1504.	0.3	3
3	Real-World Data of Trastuzumab Deruxtecan for Advanced Gastric Cancer: A Multi-Institutional Retrospective Study. Journal of Clinical Medicine, 2022, 11, 2247.	1.0	2
4	Impact of early tumor shrinkage on quality of life in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: results of Phase II QUACK trial. BMC Cancer, 2022, 22, .	1.1	1
5	Phase II Study of Panitumumab Monotherapy in Chemotherapy-NaÃ ⁻ ve Frail or Elderly Patients with Unresectable <i>RAS</i> Wild-Type Colorectal Cancer: OCSG 1602. Oncologist, 2021, 26, 17-e47.	1.9	13
6	Phase 1 study of Gemcitabine/Nab-paclitaxel/S-1 in patients with unresectable pancreatic cancer (GeNeS1S trial). Cancer Chemotherapy and Pharmacology, 2021, 87, 65-71.	1.1	3
7	Quadruplet regimen with capecitabine, irinotecan, oxaliplatin, and bevacizumab in chemo-naive patients with metastatic colorectal cancer: Results from the safety lead-in of QUATTRO-II study Journal of Clinical Oncology, 2021, 39, 57-57.	0.8	0
8	Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Patients With Active Cancer. In Vivo, 2021, 35, 2747-2753.	0.6	2
9	Safety analysis of the randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13) Journal of Clinical Oncology, 2021, 39, 86-86.	0.8	1
10	Phase II study of an oxaliplatin-based regimen for relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy (INSPIRE study). Cancer Chemotherapy and Pharmacology, 2021, 87, 665-672.	1.1	1
11	Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: A retrospective observational study using an administrative database. PLoS ONE, 2021, 16, e0246160.	1.1	7
12	Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study. International Journal of Clinical Oncology, 2021, 26, 1238-1247.	1.0	2
13	Phase II study of panitumumab monotherapy in chemotherapy-naÃ ⁻ ve frail or elderly patients with unresectable, RAS wild type colorectal cancer: OGSG 1602, survival update data Journal of Clinical Oncology, 2021, 39, 3558-3558.	0.8	0
14	Profiling plasma angiogenesis factors after use of biologics in metastatic colorectal cancer (mCRC): Update results from GI-SCREEN CRC Ukit study Journal of Clinical Oncology, 2021, 39, 3529-3529.	0.8	1
15	Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan. BMC Cancer, 2021, 21, 518.	1.1	16
16	Hepatectomy Followed by Adjuvant Chemotherapy with 3-Month Capecitabine Plus Oxaliplatin for Colorectal Cancer Liver Metastases. Oncologist, 2021, 26, e1125-e1132.	1.9	3
17	Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a firstâ€line treatment for metastatic colorectal cancer: Safety leadâ€in results from the QUATTRO-II study. Investigational New Drugs, 2021, 39, 1649-1655.	1.2	3
18	MO37-5 Efficacy of liquid biopsy testing for comprehensive cancer genome profiling in 88 cases. Annals of Oncology, 2021, 32, S322.	0.6	0

#	Article	IF	CITATIONS
19	18F-FDG-PET/CT as an imaging biomarker for regorafenib efficacy in metastatic colorectal cancer (JACCRO CC-12). Oncology and Therapy, 2021, 9, 635-645.	1.0	2
20	Dexamethasone 8 mg for Cancer-Related Fatigue in Inpatients with Advanced Cancer Undergoing Palliative Care: A Multicenter Phase II Trial. Palliative Medicine Reports, 2021, 2, 316-323.	0.4	2
21	A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure–Toxicity Analysis ofÂUnbound Regorafenib and Its Active Metabolites (RESET Trial). Clinical Colorectal Cancer, 2020, 19, 13-21.e3.	1.0	17
22	Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B. Cancer Chemotherapy and Pharmacology, 2020, 85, 217-223.	1.1	13
23	A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy. Cancer Chemotherapy and Pharmacology, 2020, 86, 607-618.	1.1	12
24	Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study). Oncologist, 2020, 25, e1855-e1863.	1.9	28
25	Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer. BMC Cancer, 2020, 20, 1116.	1.1	2
26	Disagreement between patient―and physicianâ€reported outcomes on symptomatic adverse events as poor prognosis in patients treated with firstâ€line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial. Cancer Medicine, 2020, 9, 9419-9430.	1.3	5
27	Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer. BMC Cancer, 2020, 20, 687.	1.1	9
28	Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment for patients with metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2020, 86, 277-284.	1.1	4
29	<i>RAS</i> Mutations in Circulating Tumor DNA and Clinical Outcomes of Rechallenge Treatment With Anti-EGFR Antibodies in Patients With Metastatic Colorectal Cancer. JCO Precision Oncology, 2020, 4, 898-911.	1.5	28
30	Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer. JAMA Oncology, 2020, 6, 1571.	3.4	611
31	Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study). International Journal of Clinical Oncology, 2020, 25, 1515-1522.	1.0	5
32	Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan. PLoS ONE, 2020, 15, e0234314.	1.1	11
33	Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study). International Journal of Clinical Oncology, 2020. 25. 1835-1843.	1.0	6
34	Multicenter prospective phase II trial of nivolumab in patients with unresectable or metastatic mucosal melanoma. International Journal of Clinical Oncology, 2020, 25, 972-977.	1.0	20
35	Patientâ€reported symptom burden as a prognostic factor in treatment with firstâ€line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial. Cancer Medicine, 2020, 9, 1779-1789.	1.3	6
36	Pembrolizumab (pembro) versus standard of care chemotherapy (chemo) in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062 Journal of Clinical Oncology, 2020, 38, 4523-4523.	0.8	9

#	Article	IF	CITATIONS
37	Phase II study of panitumumab monotherapy in chemotherapy-naÃ⁻ve frail or elderly patients with unresectable, RAS wild-type colorectal cancer: OGSG 1602 Journal of Clinical Oncology, 2020, 38, 106-106.	0.8	1
38	RAS status in circulating-tumor DNA (ctDNA) and outcomes during rechallenge treatments with anti-EGFR antibodies in metastatic colorectal cancer (mCRC) Journal of Clinical Oncology, 2020, 38, 166-166.	0.8	0
39	Final results of multicenter phase lb/ II study of biweekly trifluridine/tipiracil with bevacizumab combination for patients with mCRC refractory to standard therapies (BiTS study) Journal of Clinical Oncology, 2020, 38, 121-121.	0.8	1
40	Quattro-II study: A multicenter randomized phase II study comparing capoxiri plus bevacizumab with FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer as the first-line treatment Journal of Clinical Oncology, 2020, 38, TPS267-TPS267.	0.8	0
41	Multicenter phase II study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PII) Journal of Clinical Oncology, 2020, 38, 399-399.	0.8	1
42	Prevalence and risk factors of hepatitis B virus reactivation in patients with solid tumors with resolved HBV infection. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 63-68.	0.7	9
43	Reduction and Escalation in the Dose of Sunitinib Were Adequately Effective against Gastrointestinal Stromal Tumor of the Small Intestine. Internal Medicine, 2019, 58, 3243-3246.	0.3	1
44	The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: a prospective observational multicenter study protocol (IVY). BMC Cancer, 2019, 19, 941.	1.1	4
45	Update on JACCRO CC-11 trial of 1st-line modified-FOLFOXIRI plus bevacizumab for RAS mutant metastatic colorectal cancer. Annals of Oncology, 2019, 30, vi96.	0.6	0
46	Safety and effectiveness of FOLFOXIRI plus molecular target drug therapy for metastatic colorectal cancer: A multicenter retrospective study. Oncotarget, 2019, 10, 1070-1084.	0.8	7
47	A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208). Annals of Surgery, 2019, 270, 230-237.	2.1	41
48	Biweekly S-1 plus oxaliplatin (SOX) reintroduction in previously treated metastatic colorectal cancer patients (ORION 2 study): a phase II study to evaluate the efficacy and safety. International Journal of Clinical Oncology, 2019, 24, 836-841.	1.0	3
49	Update on phase II trial of cetuximab plus S-1/oxaliplatin (SOX) for metastatic colorectal cancer (mCRC): JACCRO CC-06. Annals of Oncology, 2019, 30, vi97.	0.6	0
50	Phase II trial of GEMOX for the advanced pancreatic cancer with family/personal history of HBOC related cancer. Annals of Oncology, 2019, 30, vi86.	0.6	0
51	Evaluation of health-related quality of life via the Computer-Based Health Evaluation System (CHES) for Japanese metastatic breast cancer patients: a single-center pilot study. Breast Cancer, 2019, 26, 255-259.	1.3	10
52	Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with <i>ALK</i> mutation. Internal Medicine, 2019, 58, 1029-1032.	0.3	19
53	Liquid biopsy for optimizing the rechallenge of cetuximab in metastatic colorectal cancer: Additional study of E-Rechallenge Trial Journal of Clinical Oncology, 2019, 37, 585-585.	0.8	7
54	Phase I/II study of panitumumab (PANI) combined with trifluridine/tipiracil (FTD/TPI) in patients (pts) with previously treated RAS wild-type (wt) metastatic colorectal cancer (mCRC): Final results of APOLLON study Journal of Clinical Oncology, 2019, 37, 624-624.	0.8	1

#	Article	IF	CITATIONS
55	Multicenter phase Ib/II study of biweekly trifluridine/tipiracil with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study) Journal of Clinical Oncology, 2019, 37, 647-647.	0.8	2
56	The combination of the changes and the value of neutrophil-to-lymphocyte ratio is useful for prediction of response for advanced gastric cancer treated with nivolumab: A multicenter retrospective study Journal of Clinical Oncology, 2019, 37, 150-150.	0.8	0
57	The diagnosis and outcomes when the outpatients receiving chemotherapy visited the emergency room: A tertiary referral center retrospective study of 734 cases Journal of Clinical Oncology, 2019, 37, 6552-6552.	0.8	0
58	Predictive factors for early mortality after initiation of regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer Journal of Clinical Oncology, 2019, 37, 3560-3560.	0.8	1
59	Clinical verification of circulating tumor RNA (ctRNA) as novel pretreatment predictor and tool for quantitative monitoring of treatment response in metastatic colorectal cancer (mCRC): A biomarker study of the DEEPER trial Journal of Clinical Oncology, 2019, 37, TPS3621-TPS3621.	0.8	1
60	Abstract 3882: Exposure-toxicity analysis of unbound regorafenib and its active metabolites by dose escalation strategy with low starting dose in patients with colorectal cancer. , 2019, , .		0
61	Abstract 3882: Exposure-toxicity analysis of unbound regorafenib and its active metabolites by dose escalation strategy with low starting dose in patients with colorectal cancer. , 2019, , .		Ο
62	Phase I study of primary treatment with 5-FU, oxaliplatin, irinotecan, levofolinate, and panitumumab combination chemotherapy in patients with advanced/recurrent colorectal cancer involving the wild-type RAS gene: the JACCRO CC-14 study. International Journal of Clinical Oncology, 2018, 23, 490-496.	1.0	10
63	Expression of multiple leukemic stem cell markers is associated with poor prognosis in <i>de novo</i> acute myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 2144-2151.	0.6	20
64	A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1202). Cancer Chemotherapy and Pharmacology, 2018, 81, 461-468.	1.1	8
65	Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study. Oncologist, 2018, 23, 7-15.	1.9	82
66	Acute Liver Failure with Diffuse Liver Metastasis from Breast Cancer, Not Detected by Computed Tomography: 2 Case Reports. Case Reports in Oncology, 2018, 11, 699-704.	0.3	10
67	Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory toÂtrastuzumab (KSCC1604). European Journal of Cancer, 2018, 105, 41-49.	1.3	58
68	Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane. Cancer Chemotherapy and Pharmacology, 2018, 82, 839-845.	1.1	9
69	A prospective Phase II study to examine the relationship between quality of life and adverse events of firstâ€ine chemotherapy plus cetuximab in patients with KRAS wildâ€type unresectable metastatic colorectal cancer: QUACK trial. Cancer Medicine, 2018, 7, 4217-4227.	1.3	12
70	Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2018, 17, e687-e697.	1.0	15
71	APOLLON: A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) Journal of Clinical Oncology, 2018, 36, 3523-3523.	0.8	7
72	A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11. Oncotarget, 2018, 9, 18811-18820.	0.8	27

#	Article	IF	CITATIONS
73	Neutrophil-to-lymphocyte ratio as a predictive or prognostic factor for gastric cancer treated with nivolumab: a multicenter retrospective study. Oncotarget, 2018, 9, 34520-34527.	0.8	53
74	Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors. World Journal of Gastrointestinal Oncology, 2018, 10, 528-531.	0.8	1
75	No Correlation between KRAS Status and Advanced Pancreatic Adenocarcinoma Survival. Cancer and Clinical Oncology, 2017, 6, 45.	0.2	1
76	Phase I Study of Neoadjuvant Chemotherapy with Capecitabine and Oxaliplatin for Locally Advanced Gastric Cancer. Anticancer Research, 2017, 37, 3703-3710.	0.5	3
77	First report of a Japanese phase I study of triplet plus bevacizumab for chemotherapy-naive metastatic colorectal cancer (J1-TRIBE study). Cancer Treatment Communications, 2015, 4, 75-80.	0.4	3
78	Regorafenib-Induced Hyperammonemic Encephalopathy in Metastatic Colon Cancer. Journal of Cancer Prevention & Current Research, 2015, 3, .	0.1	1
79	Feasibility of Outpatient Chemotherapy with S-1 and Cisplatin for Gastric Cancer. Journal of Cancer Therapy, 2014, 05, 759-765.	0.1	1